Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2341-2351

  Sirisoma, Nilantha ^a   Pervin, Azra ^a   Zhang, Hong ^a   Jiang, Songchun ^a   Willardsen, J Adam ^b,c   Anderson, Mark B ^b   Mather, Gary ^b   Pleiman, Christopher M ^b   Kasibhatla, Shailaja ^a   Tseng, Ben ^a   Drewe, John ^a   Cai, Sui Xiong ^a  

^a EpiCept Corporation   (United States)

^b Myriad Pharmaceuticals Inc   (United States)

^c Myriad Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (DIMETHYLAMINOMETHYL) N ( METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 CHLORO N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 CHLOROMETHYL N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 ETHYL N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 FLUOROMETHYL N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 HYDRAZINO N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 HYDROXYMETHYL N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2 METHOXY N (4 METHOXYPHENYL) N METHYLQUINAZOLIN 4 AMINE; 2,N DIMETHYL N (4 NITROPHENYL)QUINAZOLIN 4 AMINE; ANTINEOPLASTIC AGENT; AZIXA; EP 128265; EP 128495; MPC 6827; MPI 0441138; N (2 FLUORO 4 METHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (3 FLUORO 4 METHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (3,4 DIMETHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 AMINOPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 DIFLUOROMETHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 ETHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 ETHYLPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 FLUOROPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (4 METHOXYPHENYL) 2 METHYLQUINAZOLIN 4 AMINE; N (4 METHYLTHIOPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (5 METHOXYPYRAZIN 2 YL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (5 METHOXYPYRIDIN 2 YL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (5 METHOXYPYRIMIDIN 2 YL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (6 DIMETHYLAMINOPYRIDIN 3 YL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N (6 METHOXYPYRIDIN 3 YL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N( 4 METHOXYPHENYL) N,2 DIMETHYLQUINAZOLIN 4 AMINE; N4 (4 METHOXYPHENYL) N2 ACETYL N2,N4 DIMETHYLQUINAZOLINE 2,4 DIAMINE; N4 (4 METHOXYPHENYL) N2,N2,N4 TRIMETHYLQUINAZOLINE 2,4 DIAMINE; N4 (4 METHOXYPHENYL) N2,N4 DIMETHYLQUINAZOLINE 2,4 DIAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BREAST CALCIFICATION; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL ASSAY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 65149091722     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801315b     Document Type: Article

References (45)

1. Varmus, H. The new era in cancer research. Science 2006, 312, 1162-1165.
2. Kingston, D. G.; Newman, D. J. Taxoids: cancer-fighting compounds from nature. Curr. Opin. Drug Discovery Dev. 2007, 10, 130-144.
3. Cross, S. A.; Lyseng-Williamson, K. A. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs 2007, 67, 2645-2654.
4. Baselga, J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312, 1175-1158.
5. Wood, L. S.; Manchen, B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin. J. Oncol. Nurs. 2007, 11, 649-656.
6. Lackey, K. E. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem. 2006, 6, 435-460.
7. Rini, B. I. Sunitinib. ExpertOpin. Pharmacother. 2007, 8, 2359-2369.
8. Roccaro, A. M.; Vacca, A.; Ribatti, D. Bortezomib in the treatment of cancer. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 397-403.
9. Rini, B. I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 2008, 14, 1286-1290.
10. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13, 1663-1674.
11. Broniscer, A.; Panetta, J. C; O'Shaughnessy, M.; Fraga, C; Bai, F.; Krasin, M. J.; Gajjar, A.; Stewart, C. F. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin. Cancer Res. 2007, 13, 1511-1515.
12. (a) Franceschi, E.; Cavallo, G.; Lonardi, S.; Magrini, E.; Tosoni, A.; Grosso, D.; Scopece, L.; Blatt, V.; Urbini, B.; Pession, A.; Tallini, G; Crino, L.; Brandes, A. A. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer 2007, 96, 1047-1051.
13. (b) Rich, J. N.; Reardon, D. A.; Peery, T.; Dowell, J. M.; Quinn, J. A.; Penne, K. L.; Wikstrand, C. J.; Van Duyn, L. B.; Dancey, J. E.; McLendon, R. E.; Kao, J. C; Stenzel, T. T.; Ahmed Rasheed, B. K.; Tourt-Uhlig, S. E.; Herndon, J. E.; Vredenburgh, J. J.; Sampson, J. H.; Friedman, A. H.; Bigner, D. D.; Friedman, H. S. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004, 22, 133-142.
14. (c) Brandes, A. A.; Franceschi, E.; Tosoni, A.; Hegi, M. E.; Stupp, R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin. Cancer Res. 2008, 14, 957-960.
15. Polli, J. W.; Humphreys, J. E.; Harmon, K. A.; Castellino, S.; O'Mara, M. J.; Olson, K. L.; John-Williams, L. S.; Koch, K. M.; Serabjit-Singh, C. J. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5- ({[2- (methylsulfonyl) ethyl]amino}-methyl) -2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 2008, 36, 695-701.
16. Lukas, R. V.; Boire, A.; Nicholas, M. K. Emerging therapies for malignant glioma. Expert Rev. Anticancer Ther. 2007, 7, S29-36.
17. Fischer, U.; Schulze-Osthoff, K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol. Rev. 2005, 57, 187-215.
18. O'Driscoll, L.; Linehan, R.; Clynes, M. Survivin: role in normal cells and in pathological conditions. Curr. Cancer Drug Targets 2003, 3, 131-152.
19. Grivicich, I.; Regner, A.; da Rocha, A. B.; Grass, L. B.; Alves, P. A.; Kayser, G. B.; Schwartsmann, G.; Henriques, J. A. Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Oncol. Res. 2005, 15, 385-392.
20. Kolomeichuk, S. N.; Bene, A.; Upreti, M.; Dennis, R. A.; Lyle, C. S.; Rajasekaran, M.; Chambers, T. C. Induction of apoptosis by vinblastine via c-Jun. autoamplification and p53-independent down-regulation of p21WAF1/CIP1. Mol. Pharmaco. 2008, 73, 128-136.
21. Kolenko, V. M.; Uzzo, R. G.; Bukowski, R.; Finke, J. H. Apoptosis 2000, 5, 17.
22. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5, 876-885.
23. (21)
24. (a) van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10, 389-399.
25. (b) Zobel, K.; Wang, L.; Varfolomeev, E.; Franklin, M. C; Elliott, L. O.; Wallweber, H. J.; Okawa, D. C; Flygare, J. A.; Vucic, D.; Fairbrother, W. J.; Deshayes, K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 2006, 1, 525-533.
26. (c) Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3933-3938.
27. Cai, S. X.; Zhang, H.-Z.; Guastella, J.; Drewe, J.; Yang, W.; Weber, E. Design and synthesis of rhodamine 110 derivative and caspase-3 substrate for enzyme and cell-based fluorescent assay. Bioorg. Med. Chem. Lett. 2001, 11, 39-42.
28. Cai, S. X.; Drewe, J.; Kasibhatla, S. A chemical genetics approach for the discovery of apoptosis inducers: from phenotypic cell based HTS assay and structure-activity relationship studies, to identification of potential anticancer agents and molecular targets. Curr. Med. Chem. 2006, 13, 2627-2644.
29. Cai, S. X.; Nguyen, B.; Jia, S.; Herich, J.; Guastella, J.; Reddy, S.; Tseng, B.; Drewe, J.; Kasibhatla, S. Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay. J. Med. Chem. 2003, 46, 2474-2481.
30. Zhang, H.-Z.; Kasibhatla, S.; Wang, Y.; Herich, J.; Guastella, J.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg. Med. Chem. 2004, 12, 309-317.
31. (a) Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Wang, Y.; Zhao, J.; Jia, S.; Herich, J.; Labreque, D.; Storer, R.; Meerovitch, K; Bouffard, D.; Rej, R.; Denis, R.; Blais, C; Lamothe, S.; Attardo, G.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group. J. Med. Chem. 2004, 47, 6299-6310.
32. (b) Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Zhao, J.; Crogan-Grundy, C; Xu, L.; Lamothe, S.; Gourdeau, H.; Denis, R.; Tseng, B.; Kasibhatla, S.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as new series of apoptosis inducers using a cell-and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7, 8-positions. J. Med. Chem. 2007, 50, 2858-2864.
33. (c) Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Crogan-Grundy, C; Labreque, D.; Bubenick, M.; Attardo, G.; Denis, R.; Lamothe, S.; Gourdeau, H.; Tseng, B.; Kasibhatla, S.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7, 8-positions. J. Med. Chem. 2008, 51, 417-423.
34. Zhang, H.-Z.; Kasibhatla, S.; Kuemmerle, J.; Kemnitzer, W.; Oliis-Mason, K.; Qui, L.; Crogran-Grundy, C; Tseng, B.; Drewe, J.; Cai, S. X. Discovery and structure activity relationship of 3-aryl-5-aryl-1, 2, 4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. J. Med. Chem. 2005, 48, 5215-5223.
35. Sirisoma, N.; Kasibhatla, S.; Nguyen, B.; Pervin, A.; Wang, Y.; Claassen, G; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of substituted 4-anilino-2- (2-pyridyl) pyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 1. Structure-activity relationships of the 4-anilino group. Bioorg. Med. Chem. 2006, 14, 7761-7773.
36. Zhang, H.-Z.; Claassen, G.; Crogan-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery and structure activity relationship of N-phenyl-1 H-pyrazolo[3, 4-b]quinolin-4-amines as a new series of potent apoptosis inducers. Bioorg. Med. Chem. 2008, 18, 222-231.
37. Sirisoma, N.; Kasibhatla, S.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M.; Baichwal, V.; Mather, G. G.; Jessing, K; Hussain, R.; Hoang, K.; Pleiman, C. M.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 2-chloro-N - (4-methoxyphenyl) -N -meth-ylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity. J. Med. Chem. 2008, 51, 4771-4779.
38. Connolly, D. J.; Lacey, P. M.; McCarthy, M.; Saunders, C. P.; Carroll, A.-M.; Goddard, R.; Guiry, P. J. Preparation and resolution of a modular class of axially chiral quinazoline-containing ligands and their application in asymmetric rhodium-catalyzed olefin hydroboration. J. Org. Chem. 2004, 69, 6572-6589.
39. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M. MPC-6827: a small molecule inhibitor of microtubule formation that is not a substrate for multi-drug resistance pumps. Cancer Res. 2007, 67, 5865-5871.
40. Neville, K.; Parise, R. A.; Thompson, P.; Aleksic, A.; Egorin, M. J.; Balis, F. M.; McGuffey, L.; McCully, C; Berg, S. L.; Blaney, S. M. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin. Cancer Res. 2004, 10, 2525-2529.
41. Heimberger, A. B.; Learn, C. A.; Archer, G. E.; McLendon, R. E.; Chewning, T. A.; Tuck, F. L.; Pracyk, J. B.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D.; Sampson, J. H. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin. Cancer Res. 2002, 8, 3496-3502.
42. Cho, S. Y.; Fox, E.; McCully, C.; Bauch, J.; Marsh, K.; Balis, F. M. Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. Cancer Chemother Pharmacol. 2007, 60, 563-567.
43. Jacobs, S. S.; Fox, E.; Dennie, C; Morgan, L. B.; McCully, C. L.; Balis, F. M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin. Cancer Res. 2005, 11, 1669-1674.
44. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49, 7559-7583.
45. Norinder, U.; Haeberlein, M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Delivery Rev. 2002, 54, 291-313.